SIGNIFICANCE OF SERUM ONCOMARKERS IN COLORECTAL ADENOCARCINOMAS OF VARYING DEGREES OF DIFFERENTIATION

Despite the existing screening programs for colorectal cancer, new markers are still being developed, including serum biomarker panels for early diagnosis, and in patients with a verified disease, panels for assessing the prognosis and probability of metastasis. Biomarker research has remained in demand in the field of Oncology for decades, but the number of recommended, clinically significant serum markers has not increased. Objective - to study the role of serum biomarkers of colorectal adenocarcinomas of different degrees of differentiation in patients of the Kazakh population. For the study, it was used an immunofluorescence method through XMap technology, which included simultaneous determination of AFP, CA 125, CA 15-3, CA 19-9, CEA, CYFRA 21-1, HE4, and osteopontin. As a result, AFP, CA 125, and CA15-3 did not show differences related to tumor tissue differentiation.The CEA in our study confirmed dependence on the degree of differentiation, but did not respond in the case of highly differentiated adenocarcinoma.The level of CA 19-9 was higher only in the groups of moderate and low-grade adenocarcinomas. Consideration of all confounding factors will allow us to better understand the biology of cancer biomarkers and improve their interpretation and indications for use.

cancer markers, adenocarcinoma, colorectal cancer

1. Показатели онкологической службы Республики Казахстан за 2017 год (статистические материалы). КазНИИОиР. 2018. 128с./ [Indicators of the cancer service of the Republic of Kazakhstan for 2017 (statistical materials). KIOR. 2018. 128 (in Russian)].

2. A Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1/M. Far, A.R. Ibrahim, M.A. Desoukyet al.//Br. J. Biomed. Sci.- 2018.-V.75(3).-P.122-127.

3. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012/H. Brody, J. Ferlay, I. Soerjomataramуе et al. //Int. J. Cancer.- 2015.-V.36(5).- P.359-386.

4. Serum CEA and CA19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia/H. Zhai,J. Huang,C. Yang et al. // Clin. Lab.-2018.- V. 64(3).-P.351-356.

5. Serum CEA and CA 19-9 levels are associated with the presence and severity of colorectal neoplasia/N.H. Kim, M.Y. Lee, J.H. Parket al.//Yonsei Med. J.- 2017.- V.58 (5).-P. 918-924.

6. Serum human epididymis protein 4 levels in colorectal cancer patients/Y.N. Kemal, G.N. Demirag, A.M. Bediret al.//Mol.Clin.Oncol. -2017. - V. 7(3).- P.481-485.

7. Clinicopathological features and prognosis of AFP-producing colorectal cancer: a single -center analysis of 20 cases/F. Ren, W. Weng, Q. Zhanget al.//Cancer Manag. Res.- 2019.- V.16(11). - P.4557-4567.

8. Gao Y. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer/Y.Gao, J.Wang, Y.Zhou, S.Sheng//Sci. Rep.- 2018.-V.1.-P.2732.

9. Otoshi T. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel)/T. Otoshi, T. Nagano, M.Tachihara//Nishimura. -2019.- V.11 (7).- P.935.

10. Ultrasensitive detection of mucin 1 biomarker by immuno-loop-mediated isothermal amplification/H. Cao, X. Fang, H. Li., H. Li et al.// Talanta. -2017.-V. 164.-P.588-592.

11. Yotsukura S. Evaluation of serum-based cancer biomarkers: A brief reviewfrom a clinical and computational viewpoint/S. Yotsukura, H. Mamitsuka//Critical Reviews in Oncology/ Hematology.-2015.-V.93(2).-P.103-115.

12. Wei R.Osteopontin - a promising biomarker for cancer therapy/R. Wei, J.P.C Wong, H.F. Kwok//Dis Markers.- 2018.- V.27.-P. 431.